This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Negri, C. Articles by Moghetti, P. Search for Related Content PubMed PubMed Citation Articles by Negri, C. Articles by Moghetti, P.

Antiandrogen Drugs Lower Serum Prostate-Specific Antigen (PSA) Levels in Hirsute Subjects: Evidence That Serum PSA Is a Marker of Androgen Action in Women¹

Division of Endocrinology and Metabolic Diseases (C.N., F.T., G.G.S., M.M., R.C., P.M.), University of Verona, I–37126 Verona; Laboratory of Clinical Chemistry (R.D.), Ospedale Maggiore, I-37126 Verona; Laboratory of Clinical Chemistry (A.F.), Ospedale San Bortolo, I-36100 Vicenza, Italy

Address correspondence and requests for reprints to: Dr. Paolo Moghetti, Divisione di Endocrinologia e Malattie del Metabolismo, Ospedale Maggiore, I-37126 Verona, Italy. E-mail: moghetti{at}iol.it

Assay by ultrasensitive methods of serum prostate-specific antigen (PSA) recently demonstrated that many women have detectable levels of this molecule. Interestingly, serum PSA concentrations were higher in hirsute than in nonhirsute subjects, suggesting that, also in females, PSA may be regulated by androgens.

To establish the potential for this assay as a biochemical marker of androgen action in women, we studied 40 hirsute subjects recruited in a double-blind, placebo-controlled, 6-month trial assessing the effects of 3 different antiandrogen drugs: spironolactone, flutamide, or finasteride. In each subject, serum PSA, free testosterone, and 3-androstanediol glucuronide were determined at baseline and at the end of treatments.

At baseline, PSA concentrations were higher in these 40 women than in 19 nonhirsute healthy controls (12.9 ± 1.5 vs. 4.9 ± 0.7 pg/mL, P = 0.03) and significantly correlated with serum free testosterone (r = 0.37, P < 0.005). After treatments, the 29 hirsute subjects given active drugs showed significant reduction of serum PSA levels (7.2 ± 1.4 vs. 14.7 ± 3.0 pg/mL, P = 0.002). This phenomenon was correlated to baseline PSA values. No change was found in the placebo group.

In conclusion, serum PSA is increased in many hirsute women. A 6-month course of antiandrogen treatments with spironolactone, flutamide, or finasteride determines a reduction of PSA levels in these subjects. These results suggest that serum PSA is a biochemical marker of androgen action in tissues of female subjects.

This article has been cited by other articles:

				M. H. Slagter, A. Scorilas, L. J.G. Gooren, W. de Ronde, A. Soosaipillai, E. J. Giltay, M. Paliouras, and E. P. Diamandis Effect of Testosterone Administration on Serum and Urine Kallikrein Concentrations in Female-to-Male Transsexuals Clin. Chem., August 1, 2006; 52(8): 1546 - 1551. [Abstract] [Full Text] [PDF]

				M. Hero, O. A. Janne, K. Nanto-Salonen, L. Dunkel, and T. Raivio Circulating Antiandrogenic Activity in Children with Congenital Adrenal Hyperplasia during Peroral Flutamide Treatment J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5141 - 5145. [Abstract] [Full Text] [PDF]

				H. F. Escobar-Morreale, S. Ávila, and J. Sancho Serum Prostate-Specific Antigen Concentrations Are Not Useful for Monitoring the Treatment of Hirsutism with Oral Contraceptive Pills J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2488 - 2492. [Abstract] [Full Text]